Odonate Therapeutics Inc (ODT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2013||Chairman of the Board, Chief Executive Officer|
|48||2016||Vice Chairman of the Board|
|37||2013||Chief Financial Officer|
|55||2017||Chief Operating Officer|
|59||2016||Senior Vice President - Biometrics|
- BRIEF-Odonate Therapeutics Q4 Loss Per Share $0.81
- BRIEF-Odonate Therapeutics Announces Initiation Of CONTESSA, A Phase 3 Study Of Tesetaxel In Patients With Locally Advanced Or Metastatic Breast Cancer
- BRIEF-Odonate Holdings Llc Reports A 11.5 Pct Stake In Odonate Therapeutics As Of Dec 6
- BRIEF-Boxer Capital LLC Reports 10.0 Pct Stake In Odonate Therapeutics As Of Dec 6
- BRIEF-Odonate Therapeutics Announces Pricing Of Initial Public Offering